$899 Million is the total value of Sarissa Capital Management LP's 12 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIIB | BIOGEN INC | $172,034,000 | -15.4% | 643,000 | 0.0% | 19.14% | -26.3% | |
| ALKS | Buy | ALKERMES PLC | $151,844,000 | +46.4% | 7,825,000 | +8.8% | 16.89% | +27.7% |
| IRWD | Buy | IRONWOOD PHARMACEUTICALS INC | $144,892,000 | +6.2% | 14,040,000 | +3.8% | 16.12% | -7.4% |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $102,406,000 | +34.2% | 928,100 | +21.3% | 11.39% | +17.0% |
| INVA | Buy | INNOVIVA INC | $89,667,000 | +22.2% | 6,414,000 | +2.8% | 9.98% | +6.5% |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $83,450,000 | +588.5% | 743,500 | +450.7% | 9.28% | +500.5% |
| MRSN | Sell | MERSANA THERAPEUTICS INC | $60,138,000 | +175.1% | 2,570,000 | -31.5% | 6.69% | +139.9% |
| ICPT | Buy | INTERCEPT PHARMACEUTICALS INC | $57,539,000 | -20.9% | 1,201,000 | +4.0% | 6.40% | -31.0% |
| ABBV | Buy | ABBVIE INC | $30,450,000 | +39965.8% | 310,150 | +30915.0% | 3.39% | +33770.0% |
| BCRX | New | BIOCRYST PHARMACEUTICALS INC | $5,122,000 | – | 1,075,000 | +100.0% | 0.57% | – |
| RGLS | REGULUS THERAPEUTICS INC | $1,262,000 | +47.9% | 1,851,851 | 0.0% | 0.14% | +28.4% | |
| MRTX | MIRATI THERAPEUTICS INC | $114,000 | +50.0% | 1,000 | 0.0% | 0.01% | +30.0% | |
| AGN | Exit | ALLERGAN PLC | $0 | – | -467,500 | -100.0% | -10.56% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.